Loading clinical trials...
Loading clinical trials...
A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
Conditions
Interventions
Olmesartan
Placebo
+1 more
Locations
79
China
Novartis Investigative Site
Chongqing, Chongqing Municipality, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Suzhou, Jiangsu, China
Novartis Investigative Site
Shenyang, Liaoning, China
Novartis Investigative Site
Xi’an, Shanxi, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Start Date
August 1, 2012
Primary Completion Date
July 1, 2013
Completion Date
July 1, 2013
Last Updated
October 23, 2015
NCT06823947
NCT06604897
NCT07448506
NCT07433790
NCT07421401
NCT07421414
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions